Dongdong Oncology Secures RMB 6 Million in Angel Funding to Expand Offline Channels and Enhance Integrated Cancer Care Services

Recently, Chen Guang, founder of the mobile oncology healthcare app “Dongdong Oncology,” revealed to VCBeat:Dongdong Oncology secured RMB 6 million in angel funding from China’s pioneering angel investor, Xue Manzi, in late March 2017.。

Chen Guang stated that after this round of financing,In addition to building a learning community for doctors and patients and providing services for new drugs and technologies, Dongdong will continue to expand its offline channel resources.

In recent years, the development of “Internet Plus” and China’s current healthcare landscape have spawned a large number of startups focused on the medical sector. Various healthcare apps have proliferated explosively, with many internet companies securing substantial investment and experiencing rapid growth. However, the vast majority failed to withstand the tests of the market and users, ultimately folding. Amidst the challenges facing mobile health and the continued cooling of healthcare investment, how has Dongdong Oncology managed to break through the competition and win the favor of investors?

Distinct from industry peers who focus on patient social networking and disease diagnosis,Dongdong Oncology is dedicated to providing patients with one-stop, in-depth oncology diagnosis and treatment services through an integrated “content + service” model.The current state of cancer treatment in China is concerning, with patients widely facing the challenges of “limited access to medical care and medications” and “significant lag in the availability of new drugs and technologies.” “Relying solely on simple online consultations is far from sufficient to meet the treatment needs of cancer patients,” said Chen Guang. “A completely new and unique system must be established for cancer diagnosis and treatment to better help patients combat this persistent disease.”

At Dongdong Oncology, through in-depth exploration of content and interaction, users experience not just “services,” but also the establishment and reshaping of a relevant knowledge system. “By cultivating patients’ preliminary understanding of cancer treatment, we can better build their confidence, enhance their ability to self-assess diagnoses, and avoid medical scams. This may even drive comprehensive progress in China’s cancer treatment system,” explained Chen Guang, describing the therapeutic framework established by Dongdong Oncology.

Dongdong Oncology Aims to Become China's Largest Precision Oncology Treatment Service PlatformCurrently, Dongdong Oncology serves nearly 100 users from Hong Kong and Macau each month, delivers content to a precision-targeted audience of over 200,000 individuals with cancer, and has provided services to nearly 20,000 cancer patients to date.

Due to the lack of sufficiently stringent access regulations in the mobile health industry, some ill-conceived and baseless cancer treatments, along with profit-driven rumors, have spread across online platforms. Chen Guang believes thatThe core of mobile healthcare services remains addressing patients’ most pressing concerns: How should cancer be treated? What medications should be taken? Which treatment approach is most effective? Dongdong Oncology aims to provide the most professional, reliable, and personalized treatment plans for patients at every stage of their disease journey.。

Dongdong Oncology will build aPhysician-Guided Digital Community for Doctors and Patients, it redefines the relationship between patients and physicians, making patient-physician interaction the cornerstone of this system, transforming their dynamic from adversarial to collaborative.

Authoritative content produced by Dodo Oncology helps patients understand their conditions and learn about the latest medications and technologies. Physicians can also leverage patient-related data to support diagnosis and treatment, provide optimal therapeutic recommendations, and enhance the level of clinical practice. By offering a platform for the latest drugs and technologies, Dodo Oncology bridges the “last mile” gap between doctors and patients. Timely follow-ups and precise treatment plans give cancer patients hope for survival.

Over the past two years, Dongdong Oncology has made significant efforts to address the lag in the availability of new drugs and technologies in China. A prime example is the PD-1 inhibitor, a star anticancer drug approved by the U.S. FDA. Successfully launched in the United States in September 2014, this medication has substantially improved disease control rates and quality of life for cancer patients. However, due to China’s unique regulatory approval system, the PD-1 inhibitor did not immediately receive marketing authorization in the country, and related research on it remained largely absent in China.

In November 2014, Dongdong Oncology launched the Chinese version of the “Guidelines for the Use of PD-1 Inhibitors (Dongdong Edition).” With the assistance of Dongdong Oncology, the first cohort of PD-1 inhibitor users in China began receiving treatment. Meanwhile, based on follow-up tracking of these patients, Dongdong Oncology completed the “Dongdong Oncology Clinical Data Report on PD-1,” which remains the largest-scale clinical data study of its kind in China to date.

Bo Caijun, who is in charge of immunotherapy research at Dodo Oncology, also revealed to VCBeat: “Dongdong Oncology has acquired PD1.CN as its official domain name and will continue to deepen its expertise in the field of PD-1 immunotherapy.。”

Where is the future of mobile health headed? Dongdong Oncology has already charted its strategic direction, Chen Guang told VCBeat,In addition to building a doctor-patient learning community and providing services for new drugs and technologies, Dongdong will continue to expand its offline channel resources.. Chen Guang stated to VCBeat: “"In the mobile healthcare sector, traffic does not hold absolute sway; only by mastering distribution channels can one seize genuine opportunities."”